US Patent

US10561651 — Methods for treating neuroblastoma

Method of Use · Assigned to Nerviano Medical Sciences SRL · Expires 2035-02-19 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

Methods for treating neuroblastoma associated with deregulated protein kinase activity are disclosed, using substituted indazole derivatives, such as Rozlytrek.

USPTO Abstract

Methods of treating neuroblastoma associated with a deregulated protein kinase activity are disclosed. The treatment may include administration of substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts therefor, as degined in the specification.

Drugs covered by this patent

Rozlytrek (entrectinib) · Roche

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2745`	—	Rozlytrek
`U-2745`	—	Rozlytrek

Patent Metadata

Patent number: US10561651
Jurisdiction: US
Classification: Method of Use
Expires: 2035-02-19
Drug substance claim: No
Drug product claim: No
Assignee: Nerviano Medical Sciences SRL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.